Sandoz CEO Saynor Signals No Change To Focus Amid Strategic Review
Novartis Unit’s Strategy Remains Unaltered As Parent Company Explores All Options
Sandoz CEO Richard Saynor has told Generics Bulletin that the firm’s focus and strategy remain “unchanged” in the wake of last week’s announcement by parent company Novartis that it was exploring its options for the generics and biosimilars business.
